GAF Healthcare
Specialty Overview

Best Hospitals for Immunotherapy for Cancer in Mumbai, India

17 medical oncology hospitals in our India network are listed in Mumbai, accredited by JCI, NABH, NABL, ISO 9001, with 6,503 beds combined.

17
Hospitals Listed
1
City
4.6
Avg. Rating
4
Accreditation Types
The Short Answer

This page lists the medical oncology hospitals in our directory offering Immunotherapy for Cancer in Mumbai, India, including Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai and others. Each listing links through to the hospital's full profile page.

Including:🇮🇳 Nanavati Super Specialty Hospital🇮🇳 Kokilaben Dhirubhai Ambani Hospital🇮🇳 Tata Memorial Hospital

Ask us about immunotherapy for cancer in Mumbai, India

Share a few details and our care coordination team will get back to you with next steps.

Compare 17 accredited hospitals for Medical Oncology in Mumbai, India

Nanavati Super Specialty Hospital Featured
Starting from$1,000

🇮🇳 Nanavati Super Specialty Hospital

Mumbai, India 5 (12 reviews) 350 beds
Why consider this hospital?
5/5 rating from 12 reviewsAccredited by JCI, NABH350 beds
Specialties & Accreditation
OncologyCardiac SurgeryNeurosciencesTransplantBariatrics
Accredited by JCI, NABH

Patients considering immunotherapy for cancer can be cared for by Nanavati Super Specialty Hospital's care team in Mumbai, India, from initial consultation through recovery. Nanavati Super Specialty Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

5/5
Rating
1950
Established
350
Beds
Mumbai, India
Location
Enquire NowView Profile
Kokilaben Dhirubhai Ambani Hospital
Starting from$1,000

🇮🇳 Kokilaben Dhirubhai Ambani Hospital

Mumbai, India 4.8 (1800 reviews) 750 beds
Why consider this hospital?
4.8/5 rating from 1800 reviewsAccredited by JCI, NABH750 bedsHas a dedicated Medical Oncology department
Specialties & Accreditation
Medical OncologyCardiac SurgeryCardiologyBreast SurgeryBariatric SurgeryVascular Surgery
Accredited by JCI, NABH

Patients considering immunotherapy for cancer can be cared for by Kokilaben Dhirubhai Ambani Hospital's Medical Oncology department in Mumbai, India, from initial consultation through recovery. Kokilaben Dhirubhai Ambani Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.8/5
Rating
2009
Established
750
Beds
Mumbai, India
Location
Enquire NowView Profile
Tata Memorial Hospital
Starting from$1,000

🇮🇳 Tata Memorial Hospital

Mumbai, India 4.8 (2500 reviews) 629 beds
Why consider this hospital?
4.8/5 rating from 2500 reviewsAccredited by NABH629 beds
Specialties & Accreditation
OncologyCancer Center
Accredited by NABH

Patients considering immunotherapy for cancer can be cared for by Tata Memorial Hospital's care team in Mumbai, India, from initial consultation through recovery. Tata Memorial Hospital, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.8/5
Rating
1941
Established
629
Beds
Mumbai, India
Location
Enquire NowView Profile
Apollo Hospitals, Navi Mumbai
Starting from$1,000

🇮🇳 Apollo Hospitals, Navi Mumbai

Mumbai, India 4.8 (512 reviews) 500 beds
Why consider this hospital?
4.8/5 rating from 512 reviewsAccredited by JCI, NABH500 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsSpine Surgery
Accredited by JCI, NABH

Patients considering immunotherapy for cancer can be cared for by Apollo Hospitals, Navi Mumbai's care team in Mumbai, India, from initial consultation through recovery. Apollo Hospitals, Navi Mumbai, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.8/5
Rating
2016
Established
500
Beds
Mumbai, India
Location
Enquire NowView Profile
Gleneagles Hospital, Mumbai
Starting from$1,000

🇮🇳 Gleneagles Hospital, Mumbai

Mumbai, India 4.8 (615 reviews) 638 beds
Why consider this hospital?
4.8/5 rating from 615 reviewsAccredited by JCI, NABH638 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsGastroenterology
Accredited by JCI, NABH

Patients considering immunotherapy for cancer can be cared for by Gleneagles Hospital, Mumbai's care team in Mumbai, India, from initial consultation through recovery. Gleneagles Hospital, Mumbai, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.8/5
Rating
2008
Established
638
Beds
Mumbai, India
Location
Enquire NowView Profile
Lilavati Hospital And Research Centre
Starting from$1,000

🇮🇳 Lilavati Hospital And Research Centre

Mumbai, India 4.8 (724 reviews) 326 beds
Why consider this hospital?
4.8/5 rating from 724 reviewsAccredited by JCI, NABH326 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsGastroenterology
Accredited by JCI, NABH

Patients considering immunotherapy for cancer can be cared for by Lilavati Hospital And Research Centre's care team in Mumbai, India, from initial consultation through recovery. Lilavati Hospital And Research Centre, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.8/5
Rating
1997
Established
326
Beds
Mumbai, India
Location
Enquire NowView Profile
Jaslok Hospital
Starting from$1,000

🇮🇳 Jaslok Hospital

Mumbai, India 4.6 (129 reviews) 350 beds
Why consider this hospital?
4.6/5 rating from 129 reviewsAccredited by NABH, NABL350 beds
Specialties & Accreditation
Cardiac SurgeryNeurosciencesOncologyOrthopedicsTransplant
Accredited by NABH, NABL

Patients considering immunotherapy for cancer can be cared for by Jaslok Hospital's care team in Mumbai, India, from initial consultation through recovery. Jaslok Hospital, accredited by NABH, NABL, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.6/5
Rating
1973
Established
350
Beds
Mumbai, India
Location
Enquire NowView Profile
Gleneagles Global Hospitals (Global Hospitals)
Starting from$1,000

🇮🇳 Gleneagles Global Hospitals (Global Hospitals)

Parel, Mumbai, India 4.6 (183 reviews) 450 beds
Why consider this hospital?
4.6/5 rating from 183 reviewsAccredited by NABH, JCI450 beds
Specialties & Accreditation
Liver TransplantCardiac SurgeryOrthopedicsOncologyNeurosciences
Accredited by NABH, JCI

Patients considering immunotherapy for cancer can be cared for by Gleneagles Global Hospitals (Global Hospitals)'s care team in Parel, Mumbai, India, from initial consultation through recovery. Gleneagles Global Hospitals (Global Hospitals), accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.6/5
Rating
1996
Established
450
Beds
Parel, Mumbai, India
Location
Enquire NowView Profile
Medicover Hospital, Navi Mumbai
Starting from$1,000

🇮🇳 Medicover Hospital, Navi Mumbai

Navi Mumbai, India 4.6 (143 reviews) 310 beds
Why consider this hospital?
4.6/5 rating from 143 reviewsAccredited by NABH310 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyOrthopedicsNeurologyGastroenterology
Accredited by NABH

Patients considering immunotherapy for cancer can be cared for by Medicover Hospital, Navi Mumbai's care team in Navi Mumbai, India, from initial consultation through recovery. Medicover Hospital, Navi Mumbai, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.6/5
Rating
2023
Established
310
Beds
Navi Mumbai, India
Location
Enquire NowView Profile
KIMS Hospitals, Thane
Starting from$1,000

🇮🇳 KIMS Hospitals, Thane

Mumbai, India 4.6 (58 reviews) 300 beds
Why consider this hospital?
4.6/5 rating from 58 reviewsAccredited by NABH300 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsSpine Surgery
Accredited by NABH

Patients considering immunotherapy for cancer can be cared for by KIMS Hospitals, Thane's care team in Mumbai, India, from initial consultation through recovery. KIMS Hospitals, Thane, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.6/5
Rating
2025
Established
300
Beds
Mumbai, India
Location
Enquire NowView Profile
Our Methodology

How we selected these hospitals

A hospital appears on this page when Medical Oncology is among its listed specialties and it is located in Mumbai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Immunotherapy for Cancer in Mumbai, India?

Choosing the right hospital for immunotherapy for cancer is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include medical oncology rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Immunotherapy for Cancer

Cancer immunotherapy harnesses the body's own immune system to identify, attack, and eliminate malignant cells — representing one of the most significant paradigm shifts in oncology over the past two decades.

3–7 days per treatment cycle (outpatient infusions are common; inpatient admission required for CAR-T cell therapy and high-grade immune-related adverse events)
Hospital Stay
2–6 weeks minimum before international travel is medically cleared; CAR-T recipients typically require 4–8 weeks of local monitoring post-infusion
Total Stay in Country (Fit-to-Fly)
Objective response rates range from 15–45% for solid tumors with PD-1/PD-L1 checkpoint inhibitors; 70–85% complete remission rates reported for relapsed/refractory B-cell lymphoma with CAR-T (axicabtagene ciloleucel / tisagenlecleucel); outcomes are highly cancer-type and biomarker dependent
Success Rate

Clinical Overview

  • Cancer immunotherapy is a class of treatments that modulates or augments the immune system's capacity to recognize tumor-associated antigens (TAAs) and mount a sustained cytotoxic response against malignant cells.
  • Unlike conventional chemotherapy — which exerts cytotoxic effects on all rapidly dividing cells — immunotherapy is designed to achieve tumor-selective killing while generating immunological memory capable of preventing relapse.
  • The principal biological targets include immune checkpoint proteins (PD-1, PD-L1, CTLA-4, LAG-3, TIM-3), tumor-infiltrating lymphocyte (TIL) pathways, and surface antigens uniquely expressed on cancer cells such as CD19, CD20, HER2, and EGFR.
Full details →

Who is a Candidate?

  • ELIGIBILITY CRITERIA:
  • Patients with histologically or cytologically confirmed solid tumors or hematologic malignancies for whom immunotherapy has regulatory approval or strong Level 1 evidence (e.g., NSCLC, melanoma, bladder cancer, RCC, HCC, MSI-H colorectal cancer, triple-negative breast cancer, classical Hodgkin lymphoma, diffuse large B-cell lymphoma)
  • Patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) or large B-cell lymphoma who have failed ≥2 prior lines of systemic therapy (CAR-T eligibility)
  • ECOG Performance Status 0–2 (patients with PS 3–4 are generally not candidates for aggressive immunotherapy unless performance decline is directly disease-related and reversible)
  • +20 more

Treatment Options & Approaches

  • CHECKPOINT INHIBITOR THERAPY (ANTI-PD-1 / PD-L1 / CTLA-4):

Recovery

  • PHASE 1 — PRE-TREATMENT EVALUATION (WEEKS 1–3, OFTEN COMPLETABLE REMOTELY):

Risks to be aware of

  • Cancer immunotherapy carries a distinct and clinically significant toxicity profile that differs fundamentally from conventional chemotherapy.
  • The most consequential category is immune-related adverse events (irAEs), which result from non-specific immune activation affecting normal tissues.
Full details →

Why GAF Healthcare

  • GAF Healthcare provides a fully integrated, end-to-end medical travel coordination service that removes logistical barriers at every stage of the immunotherapy journey, allowing patients and their families to focus entirely on treatment and recovery.

Cost Range for Related Procedures

Cancer Surgery$4,000–$15,000
Chemotherapy$1,000–$4,000
Radiation Therapy$3,500–$10,000
Get a personalised estimate with our cost calculator →

Common questions about Immunotherapy for Cancer

What is the cost of Cancer Immunotherapy in India vs. the UAE?
The cost of cancer immunotherapy varies considerably depending on the specific agent or combination regimen, the number of treatment cycles required, and whether advanced modalities such as CAR-T cell therapy are part of the protocol. In India, a full course of checkpoint inhibitor therapy (e.g., pembrolizumab every 3 weeks for 6–12 months) typically costs between USD 8,000 and USD 45,000, while CAR-T cell therapy (including leukapheresis, manufacturing logistics, conditioning chemotherapy, infusion, and monitoring) ranges from approximately USD 40,000 to USD 75,000 at leading JCI- and NABH-accredited oncology centers in Mumbai, Delhi, Chennai, and Hyderabad. In the UAE (Dubai and Abu Dhabi), equivalent checkpoint inhibitor protocols range from USD 18,000 to USD 65,000, while CAR-T programs at JCI/DHA-accredited hospitals in Dubai Healthcare City and Abu Dhabi typically range from USD 80,000 to USD 140,000 — still representing a 60–70% cost reduction compared to the United States, where CAR-T product costs alone exceed USD 375,000–465,000 before hospital fees. The cost advantage in India is primarily driven by lower drug acquisition costs (domestic manufacturing of biosimilar checkpoint inhibitors is permitted), lower operational costs, and high treatment volume. The UAE commands a premium reflecting luxury hospital infrastructure, advanced nursing ratios, and geographic convenience for patients from the Middle East, GCC, and Africa. In both destinations, GAF Healthcare provides transparent, itemized cost estimates with no hidden fees before any commitment is made.
How long do I need to stay in the country before I am fit to fly home?
The minimum in-country stay required before you are medically cleared for international air travel depends significantly on the specific immunotherapy modality you receive. For checkpoint inhibitor therapy (pembrolizumab, nivolumab, ipilimumab, or combination regimens): The initial workup, biomarker testing, and Cycle 1 administration typically require 2–3 weeks in-country. Once Cycle 1 is complete and no Grade 2 or higher immune-related adverse events (irAEs) are present, most patients receive fit-to-fly clearance after 3–4 weeks total. Subsequent cycles (typically every 3–6 weeks) can often be administered at a GAF Healthcare partner facility closer to your home country. For CAR-T cell therapy: This requires a longer and non-negotiable in-country commitment. After leukapheresis (Day 1), there is typically a 2–4 week wait for cell manufacturing. Lymphodepleting chemotherapy begins 2–3 days before CAR-T infusion. Post-infusion, a minimum of 4 weeks of mandatory inpatient and outpatient monitoring is required to manage cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which can onset up to Day 14. A 28–30 day response assessment PET-CT is performed before discharge planning begins. The minimum realistic total in-country duration for CAR-T patients is 8–10 weeks. For all patients, a formal fit-to-fly letter is issued by the treating oncologist, and GAF Healthcare provides a structured medical summary for cabin crew and customs if required. Long-haul flights carry additional DVT risk in immunocompromised patients, and low-molecular-weight heparin prophylaxis may be recommended depending on thrombotic risk assessment.
What is the success rate of Cancer Immunotherapy?
The success rate of cancer immunotherapy is highly context-dependent and must be interpreted based on cancer type, molecular biomarker profile, treatment line, and the specific modality used. There is no single universal success rate; the figures below reflect the strongest published clinical data. For PD-1/PD-L1 checkpoint inhibitors in solid tumors: Objective response rates (ORR) range from 15–45% depending on PD-L1 expression and TMB status. In NSCLC with PD-L1 TPS ≥50%, pembrolizumab monotherapy achieves an ORR of approximately 45% and a 5-year overall survival rate of ~31% (Keynote-024 long-term follow-up). In metastatic melanoma treated with dual checkpoint blockade (nivolumab + ipilimumab), 5-year overall survival is approximately 52% (CheckMate 067). Patients with MSI-H/dMMR tumors across any cancer type treated with pembrolizumab or dostarlimab demonstrate ORRs of 40–57%, with a significant subset achieving durable complete responses. For CAR-T cell therapy: In relapsed/refractory large B-cell lymphoma, axicabtagene ciloleucel achieves complete remission rates of 58–73% in the third-line setting, with approximately 40% of patients maintaining response at 24 months. In relapsed/refractory B-cell ALL in pediatric/young adult patients, tisagenlecleucel achieves complete remission in approximately 81% of cases. For multiple myeloma treated with BCMA-targeting CAR-T (ciltacabtagene autoleucel), ORRs exceed 98% with stringent complete response rates of ~73% in heavily pretreated populations. It is essential to understand that 'success' in oncology is measured across multiple endpoints: overall survival, progression-free survival, complete remission, quality of life, and durable disease control. GAF Healthcare's partner oncologists provide individualized probability estimates based on your specific tumor profile, biomarker results, and treatment history during the initial teleconsultation — before any financial or travel commitment is made.

Related pages

How GAF Healthcare Assists in Choosing the Best Hospital for Immunotherapy for Cancer in Mumbai, India

Discover the Top Hospitals for Immunotherapy for Cancer in Mumbai, India

This page lists 17 accredited medical oncology hospitals in Mumbai, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Common Questions

Frequently asked questions about immunotherapy for cancer in Mumbai, India

How many medical oncology hospitals are listed in Mumbai, India?
17 hospitals in our Mumbai, India directory are currently listed for medical oncology including Immunotherapy for Cancer.
How do you choose which hospitals to list?
A hospital appears on this page when Medical Oncology is among its listed specialties and it is located in Mumbai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there medical oncology hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
Are these hospitals internationally accredited?
Hospitals listed on this page carry accreditations including JCI, NABH, NABL, ISO 9001 — see the accreditation badge shown for each hospital below.
Can I get a treatment plan and cost estimate before I travel?
Yes. Share your medical reports with the GAF Healthcare team over WhatsApp or email, and our medical team will review them and come back with a recommended hospital, a treatment plan and an itemised cost estimate before you commit to anything.
Do you help with visa, travel and accommodation?
Yes. Once you choose a hospital, our team helps arrange the medical visa invitation letter, book accommodation near the hospital, and organise airport pickup and transport to appointments.
What support do I get during and after treatment?
Our medical team reviews your reports and stays in touch throughout your treatment journey — from the first consultation through recovery, including after you return home.
What does the "Featured" label next to a hospital's name mean?
"Featured" reflects editorial prominence on this listing, not a clinical ranking or a claim that it is the "best" hospital.
How do I get matched with the right hospital for immunotherapy for cancer?
Share your medical reports and requirements with the GAF Healthcare team, and our medical coordinators will recommend a suitable hospital from this list based on your case.
Does the listed cost cover everything?
The figures shown are an indicative planning estimate, not a final quote from a specific hospital. Our team provides a single, itemised, all-inclusive quote before you make any commitment.
🤔

Still have questions?

Our coordinators are here to answer your questions about immunotherapy for cancer in Mumbai, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for immunotherapy for cancer in Mumbai, India.

Contact us to report an inaccuracy on this page.

WhatsApp Us